DocWire News Editors

DocwireNews

When it comes to&nbsp;vascular disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), the interferon (IFN) signature&nbsp;represents&nbsp;a therapeutic target that has shown promise.&nbsp;In this study published in&nbsp;Annals of the Rheumatic Diseases,&nbsp;researchers attempt to find an&nbsp;easy to measure biomarker for the IFN signature.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the <a href="https://twitter.com/hashtag/interferon?src=hash&amp;ref_src=twsrc%5Etfw">#interferon</a> signature in patients with systemic <a href="https://twitter.com/hashtag/lupus?src=hash&amp;ref_src=twsrc%5Etfw">#lupus</a> and <a href="https://twitter.com/hashtag/antiphospholipid?src=hash&amp;ref_src=twsrc%5Etfw">#antiphospholipid</a> syndrome.<a href="https://t.co/frKAif8x03">https://t.co/frKAif8x03</a> <a href="https://t.co/eBQZ3Nbz5f">pic.twitter.com/eBQZ3Nbz5f</a>
&mdash; Annals of the Rheumatic Diseases (@ARD_BMJ) <a href="https://twitter.com/ARD_BMJ/status/1037733353737388032?ref_src=twsrc%5Etfw">September 6, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>In the study, researchers looked at the serum levels of galectin-9, CXCL-10 (IP-10) and tumor necrosis factor receptor type II (TNF-RII)&nbsp;in&nbsp;patients with SLE, SLE+APS&thinsp;and primary APS (PAPS) and healthy controls (n=148) after an initial screening of serum analytes in a smaller cohort (n=43).&nbsp;Researchers looked at&nbsp;galectin-9, CXCL-10,&nbsp;and TNF-RII as biomarkers to detect the IFN signature was assessed by receiver operating characteristic curves.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
.<a href="https://twitter.com/RadstakeImmunol?ref_src=twsrc%5Etfw">@RadstakeImmunol</a> has taken our observation of an interferon signature in primary antiphospholipid syndrome and run with it. Nice work.
Interestingly, we have found Galectin-9 upregulated in APS neutrophils. Seems very credible as a potential biomarker.<a href="https://t.co/cCQAT8oPYb">https://t.co/cCQAT8oPYb</a>
&mdash; Jason S Knight (@jasonsknight) <a href="https://twitter.com/jasonsknight/status/1037665603811766273?ref_src=twsrc%5Etfw">September 6, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Results showed that&nbsp;galectin-9, CXCL-10, and TNF-RII were elevated in patients with SLE, SLE+APS&thinsp;and PAPS (p&lt;0.05) and correlated with disease activity and tissue factor expression.&nbsp;&ldquo;Galectin-9 is a novel, easy to measure hence clinically applicable biomarker to detect the IFN signature in patients with systemic autoimmune diseases such as SLE and APS,&rdquo; the researchers concluded.&nbsp;Check out&nbsp;an article on&nbsp;knee osteoarthritis and its&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/knee-osteoarthritis-obesity/">link to obesity</a>.&nbsp;SOURCE:&nbsp;<a href="https://ard.bmj.com/content/early/2018/09/05/annrheumdis-2018-213497">Annals of the Rheumatic Diseases</a>&nbsp;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Establishing an Easy-to-Measure Biomarker for the IFN Signature

Rheumatology

When it comes to vascular disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), the interferon (IFN) signature represents a therapeutic target ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe